Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Creo Medical Group Plc LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 210.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
204.00 210.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 9.43 -13.00 332
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 210.00 GBX

Creo Medical (CREO) Latest News

More Creo Medical News
Creo Medical Investors    Creo Medical Takeover Rumours

Creo Medical (CREO) Discussions and Chat

Creo Medical Forums and Chat

Date Time Title Posts
10/6/202121:26Creo Medical Group... 2017407
03/12/201812:41First use of Speedboat in mainland Europe-
09/12/201614:52China Real Estate Opportunities3
27/6/201212:52having a look......1,095

Add a New Thread

Creo Medical (CREO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Creo Medical trades in real-time

Creo Medical (CREO) Top Chat Posts

DateSubject
23/6/2021
09:20
Creo Medical Daily Update: Creo Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 206p.
Creo Medical Group Plc has a 4 week average price of 202p and a 12 week average price of 185p.
The 1 year high share price is 234p while the 1 year low share price is currently 141.50p.
There are currently 157,940,390 shares in issue and the average daily traded volume is 106,989 shares. The market capitalisation of Creo Medical Group Plc is £331,674,819.
04/6/2021
14:04
rambutan2: Final results for the 12 months ended 31 December 2020 A Transformational Year: Significant growth and continued regulatory progress Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces its audited final results for the 12 months ended 31 December 2020 . The Board is pleased to be able to report that, despite the COVID-19 pandemic, the year ended 31 December 2020 was a strong period for Creo marked by significant internal development and expansion, along with the continued development of the Company's suite of devices to complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy. hTtps://creomedical.com/wp-content/uploads/2021/06/Creo-Medical-Group-plc-2020-Annual-Reports-and-Accounts.pdf
15/5/2021
15:28
tonsil: IIs own 68 % of Creo. BG are one of largest holders. I take that as a big positive hTTps://simplywall.st/stocks/gb/healthcare/aim-creo/creo-medical-shares/news/what-is-the-ownership-structure-like-for-creo-medical-limite/amp
17/2/2021
15:36
edwardt: love this line in the announcement. "At the start of the pandemic, we asked the Creo team to focus on what they can achieve not what they can't achieve; I believe that they have done just that". you can assess the product range and the financials all day long as an investor but culture is also very important too imo!
25/1/2021
15:42
pecuniarum copia: I wonder if we will have a TU this week? Followed with a new ATH, of course. also... httPs://twitter.com/CreoMedical/status/1351528137805410306 1:53 PM · Jan 19, 2021 Creo Medical @CreoMedical We're delighted to announce that Creo was recently awarded onto the Endoscopy Consumables Supply Chain Agreement with NHS England. We're excited that more #patients will have access to our state of the art technology & help us deliver on our commitment to better clinical outcomes
07/1/2021
10:17
dplewis1: Well the market cap is pricing in some decent revenues as it is.. I wouldn't say CREO is a 'cheap' AIM share
22/12/2020
12:47
someuwin: Creo Medical @CreoMedical ·29m We are thrilled to support the product development of IQ Endoscopes disruptive technology, a range of single use flexible #endoscopes for diagnostics and therapeutic procedures. #IQscope @CreoEndoscopy @devbankwales https://developmentbank.wales/news-and-events/iq-endoscopes-secures-development-bank-wales-and-creo-medical-led-ps15m-funding
30/11/2020
10:16
someuwin: Last Friday PM boris visited PHE (Public Health England) and DSTL at Porton Down. Talking about Covid. The news report I saw showed one of the things they're working on, trialling a new way of sanitising ambulances from Covid using what they called 'aerosols'. As we know, CREO were awarded £2m from Cardiff Capital Region to develop their Cool Plasma product for sanitising and killing covid. This link to gov website shows that Welsh Ambulance Service are involved. https://www.gov.uk/government/news/covid-19-call-for-rapid-sanitising-technology-for-ambulances The pic above from last Friday at Porton shows a Welsh Ambulance Service being tested. If you watch this video at this CREO link you can see a mock up of an ambulance being decontaminated with their tech... https://www.creomedical.com/2020/07/08/development-loan-for-plasma-sterilising-product/ Joining the dots, I think what they showed on the news last Friday was CREO's Cool Plasma tech undergoing Covid trials at Porton Down! If so, watch out for potentially very good news soon - imo.
11/2/2019
07:07
someuwin: Creo Medical Group plc ("Creo" or the "Company") Additional European Framework Distribution Agreement with PENTAX Medical Agreement covering France, Germany and Italy Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has entered into a framework distribution agreement with PENTAX Europe GmbH ("PENTAX Europe") to provide clinical training and market seeding across the French, German, and Italian markets, for Creo's CROMA advance energy platform and Speedboat products. Continuing Creo's education led commercial strategy, Pentax Europe will collaborate with Creo over an 18-month period to advance the roll out of Creo's Clinical Education Programme across these key markets in Europe, educating leading clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes. Creo's Clinical Education Programme ensures that distributor trainers, having been carefully mentored by Creo's doctors and endoscopy nurses, can deliver training for clinicians at a consistently high standard within their local markets. PENTAX Europe will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed. This agreement follows on from the PENTAX Medical (a division of HOYA Group) distribution agreement covering Asia-Pacific (APAC) which was extended in September last year, as well as the recently announced agreements covering Spain, the Netherlands, Belgium and Luxembourg. In addition, distribution agreements have already been signed covering the UK and South Africa. Creo's CROMA advanced energy platform combines bipolar radiofrequency for precise localised cutting and microwave energy for controlled coagulation. Speedboat is the first product approved in a suite of tools under development to aid the endoscopist in minimally invasive surgery. The Speedboat device helps reduce the risks associated with alternative open and laparoscopic procedures, reducing the length of hospital stays, cost of treatment and transfers therapy from the operating theatre to the endoscopy room. PENTAX Medical has identified endoscopic therapeutic devices as a priority area in its growth strategy, and this agreement with Creo Medical Ltd. accelerates PENTAX Medical's expansion of their footprint in the therapeutics segment through a lineup of differentiated products. Flexible endoscopes have been developed for use in minimally invasive treatment procedures, in combination with therapeutic devices. These scopes are gaining worldwide interest and adoption for their clinical and financial benefits, as well as in the realization of highly advanced surgeries in gastroenterology and other applications. Craig Gulliford, Chief Executive Officer of Creo, commented: "Entering mainland Europe was an important milestone for Creo, but a commercialisation strategy that encompasses the major healthcare markets of France and Germany is key for the successful European roll-out of our lead product, Speedboat, powered by our CROMA advanced energy platform. This further agreement reinforces our strategy of growing our distribution network and reputation both in Europe and worldwide, positioning us as a leading innovator in the emerging field of surgical endoscopy." Rainer Burkard, President, PENTAX Europe GmbH commented: "We are pleased to deliver our customers more clinical outcomes, patient experiences and efficiency seamlessly with PENTAX Medical's cutting-edge flexible endoscopes and therapeutics portfolio. This agreement grants us access to an innovative electrosurgical platform and accelerates PENTAX Medical's strategy of more effectively serving physicians and their patients in a rapidly evolving health care industry by expanding into the vital endoscopic therapy space."
17/9/2018
07:12
someuwin: Creo Medical Group plc Extension of Distribution Agreement with Hoya Pentax Medical for the Asia-Pacific (APAC) region Creo Medical Education Programme to be initiated in APAC alongside Market Seeding beginning in Australia. Chepstow, Wales - 17 September 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has entered into an addendum to its distribution agreement with Hoya Group, Pentax Medical ("Pentax"). Under the terms of the original distribution agreement, Creo granted Pentax the right to distribute Creo's Speedboat product and CROMA platform in the Asia Pacific region for 5 years subject to agreement of final terms by territory. The addendum further entrenches Creo's relationship with Pentax with firm commitment to roll out to various territories in conjunction with establishing Creo's Clinical Education Program and thereafter seeding the chosen markets. Australia will be the first Asia Pacific territory in which Pentax will establish Creo's Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within 3 months. Furthermore, Creo has agreed to extend the term of Pentax's distribution rights in each territory in which Pentax establishes Creo's Clinical Education Programme for a period of 5 years from the date on which Creo's products are registered in such territory. Creo has commenced the regulatory registration process for its products in Australia and in conjunction with Pentax Creo has begun introducing doctors from Australia and other territories to the clinical education program here in Europe which will be rolled out into APAC in the coming months. CROMA's electrosurgical platform combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. Speedboat is the first product approved in a suite of tools under development to aid the endoscopist in minimally invasive surgery. The Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room. Craig Gulliford, Chief Executive Officer, commented: "The extension of our agreement with Pentax marks a significant milestone in the commercialisation of Speedboat, our lead product. Creo is dedicated to improving patient outcomes and helping clinicians by bringing advanced energy to the emerging field of surgical endoscopy. Speedboat is paving the way for our suite of GI devices under development. Our products are rapidly gaining traction in the endoscopic field and with Pentax as our partner in the Asia Pacific region, their expertise and knowledge will prove invaluable to Creo in these important markets and as we build our reputation worldwide." David Woods, President and CEO of Pentax Americas and M&A Director, commented: "As a leading supplier of innovative and advanced medical products for minimally invasive procedures we recognise the great potential of the CROMA platform and Speedboat. I am pleased that we have been able to deepen our relationship with Creo. Ultimately, under this expanded commercial agreement more patients will benefit from the power of precise cutting and controlled coagulation, leading to better clinical outcomes in an outpatient setting."
04/1/2017
09:56
pecuniarum copia: Creo Medical Group is focused on the development and commercialisation of minimally invasive surgical devices, initially in the area of gastrointestinal (GI) surgery and lung cancer. Creo Medical Group has conditionally raised £20 million through a placing with institutional and other investors at a placing price of 76 pence per ordinary share. Market capitalisation approximately £61.3 million. PROPOSED PLACING OF 26,315,800 NEW ORDINARY SHARES AT 76 PENCE PER SHARE AND ADMISSION TO TRADING ON AIM Creo Medical Group PLC (CREO), admission to the AIM Market, 9 December 2016. 80,711,745 Issued and fully paid Ordinary Shares of £0.001 each httPs://find-and-update.company-information.service.gov.uk/company/10371794 x x x AIM rule 26 httPs://investors.creomedical.com/investors/rule-26 RNS: 19 April 2021 Exercise of Options CREO… has issued, conditional on admission, 49,209 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options. It is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on 23 April 2021 Following admission, the Company will have 157,940,390 Ordinary Shares in issue. This figure of 157,940,390 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules. x x x https://twitter.com/creomedical?lang=en https://twitter.com/CreoMedical/status/1275002010971123713 [22 June 2020] And we're live! We're so excited to share our new website! Join us on our journey to improve patient outcomes with #AdvancedEnergy. Explore: httP://creomedical.com CREO Admission Document, Dec.2016, PDF httPs://investors.creomedical.com/~/media/Files/C/Creo-Medical/investor-docs/results-and-presentations/creo-admission-document-final.pdf 2019 AIM Awards ~ Best AIM companies > Technology = Creo Medical httPs://www.ii.co.uk/analysis-commentary/best-aim-companies-2019-confirmed-ii509438 2020 Video Abstracts ~ Use of Speedboat-RS2... RNS: 11 February 2020 - Video abstracts featuring Speedboat procedures in India httPs://www.videogie.org/article/S2468-4481(19)30344-3/fulltext and also [...] RNS: 3 August 2020 ~ Video abstract published endorsing Speedboat procedure The video abstract, published via an open access content publisher, Thieme Group titled: 'Feasibility of Speedboat RS2 with bipolar radiofrequency energy for peroral endoscopic myotomy in patients with achalasia (with video)' can be viewed online here: [...] x x x RESULTS Info... Documents are available on the Company's website: httPs://investors.creomedical.com/investors/reports-and-presentations Chepstow, Wales - 20 April 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, announces that it has changed its accounting reference date from 30 June to 31 December with immediate effect. Interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies. Unaudited interims for the 6 month period ending 30 June 2018 to be published by 30 September 2018, and Audited results for the 18 month period to 31 December 2018 to be published by 30 April 2019. Note: 5 April 2019, CREO published Full results for the 18 months ended 31 December 2018. x x x Follow Link for Latest Shareholding Info... AIM rule 26 httPs://investors.creomedical.com/investors/rule-26 Latest Shareholding RNS... 13 July 2018: Conditional Placing of new Ordinary Shares [@ 125.pence] 23 December 2019: Result of Open Offer [@ 180.pence] 24 December 2019: Director / PDMR Shareholding 27 December 2019: Legal & General Assurance Soc. (LGAS) Below 3% from 3.26% 30 December 2019: TR-1 M&G Plc 5.54% from n/a 07 February 2020: Exercise of Options 19 February 2020: Issue of Equity and Long Term Incentive Plan ("LTIP") 04 March 2020: Exercise of Options 24 July 2020: Director / PDMR Shareholding 11 August 2020: Exercise of Options 24 November 2020: Exercise of Options 19 April 2021: Exercise of Options 30 April 2021: Total Voting Rights (157,940,390) x x x RNS UPDATE... RNS: 13 September 2018 First placement and use of Speedboat in South Africa. Seven upper GI tract patients successfully treated. Creo… today announces the successful first use of its Speedboat endoscopic advanced energy device in the upper gastrointestinal tract (GI) in seven patients in South Africa. This follows the appointment of the Company's South African sales and distribution partner, First Medical Company, in July 2018... RNS: 17 September 2018 Extension of Distribution Agreement with Hoya Pentax Medical for the Asia-Pacific (APAC) region. Creo Medical Education Programme to be initiated in APAC alongside Market Seeding beginning in Australia. ...Australia will be the first Asia Pacific territory in which Pentax will establish Creo's Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within 3 months. Furthermore, Creo has agreed to extend the term of Pentax's distribution rights in each territory in which Pentax establishes Creo's Clinical Education Programme for a period of 5 years from the date on which Creo's products are registered in such territory... RNS: 17 October 2018 Spain & Benelux Framework Distribution Agreements Agreements covering Spain, the Netherlands, Belgium and Luxembourg First shipment of products to mainland Europe Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has entered into two further framework distribution agreements to provide clinical training and market seeding across the Spanish, Belgian, Dutch and Luxembourg markets for Creo's CROMA advance energy platform and Speedboat products, ahead of their full commercial launch in 2019. RNS: 3 December 2018 First placement and use of Speedboat in Europe Creo… announces the successful first treatment of a patient in mainland Europe using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform, in Seville, Spain. Craig Gulliford, Creo's Chief Executive Officer, commented: "Mainland Europe and the US are key markets for the Company and the successful completion of the first procedure in Spain is an important milestone as we roll-out our Clinical Education Programme across Europe initially through our distribution partners covering Spain, the Netherlands, Belgium and Luxembourg. The additional funds raised over the summer have allowed us to expand our training programme to target a wider international group of clinicians and we remain on track with our US commercialisation programme and look forward to updating shareholders on positive progress." RNS: 16 January 2019 First use of Speedboat in the US Creo... announces the successful first treatment of patients in the US using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform. Craig Gulliford, Creo's Chief Executive Officer, commented: "The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances." RNS: 11 February 2019 Additional European Framework Distribution Agreement with PENTAX Medical Agreement covering France, Germany and Italy ...Continuing Creo's education led commercial strategy, Pentax Europe will collaborate with Creo over an 18-month period to advance the roll out of Creo's Clinical Education Programme across these key markets in Europe, educating leading clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes... ...PENTAX Europe will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed. This agreement follows on from the PENTAX Medical (a division of HOYA Group) distribution agreement covering Asia-Pacific (APAC) which was extended in September last year, as well as the recently announced agreements covering Spain, the Netherlands, Belgium and Luxembourg. In addition, distribution agreements have already been signed covering the UK and South Africa... RNS: 28 March 2019 Update on US Clinical Education Programme Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist. This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme. RNS: 25 June 2019 First commercial orders for Speedboat Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received its first commercial orders for its Speedboat device, the first in a range of gastrointestinal ('GI') devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. The first purchase orders come from two US hospitals and follow on from the successful roll out of the Company's Clinical Education Programme in the US which has now trained seven leading GI Endoscopists across six hospitals. The purchase orders are a follow-on order of the disposable Speedboat devices following the initial sales of products for training purposes... RNS: 10 September 2019 US Clinical Education Programme enters Phase II First training course delivered by key US adopter trained by Creo ...As part of this new phase, three additional US clinicians have been trained by a US GI Endoscopists who performed his first clinical case earlier this year (RNS 1927N, 16 January 2019) and practices at a major US hospital, which was one of the first to place commercial orders for the Company's Speedboat device. RNS: 26 September 2019 Framework Distribution Agreement for India Indian doctors and nurses trained on Speedboat following signing CREO... has entered into a Distribution Partner Framework Agreement (the "Agreement") with MEDITEK SYSTEMS ("Meditek"), to provide clinical training and market seeding across the Indian market for Creo's CROMA Advance Energy platform and suite of products, including the Speedboat device, ahead of their official launch. RNS: 22 October 2019 Commercial Launch of Speedboat at UEG Week in Barcelona [21/23 Oct.19] Demonstration of wider suite of gastro-intestinal products awaiting regulatory clearance ...Creo will be exhibiting at the United European Gastroenterology ('UEG') Week Congress in Barcelona from 21-23, October 2019 show-casing the CROMA Platform... Craig Gulliford, Chief Executive Officer, commented: "The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the Company. In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020." RNS: 20 November 2019 First in-human cases in India Asia's First POEM procedure undertaken using Speedboat Creo… announces that the first mentored, in-human use of its Speedboat device has taken place in India. This announcement follows on from the framework distribution agreement the Company signed with Meditek Systems in September 2019 to provide clinical in-country training, mentoring and market seeding in India for Creo's CROMA Advanced Energy Platform and suite of products. To date, Medical staff from six key healthcare institutions across India have completed training as part of Creo's Clinical Education Programme and the start of in-country mentoring was marked with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat. These are the first POEM procedures in India carried out using the Speedboat device and show the significant advances made towards the future of endoscopic surgery. The procedures were performed by Dr Amit Maydeo and Dr Gaurav Patil at the BIDS (Baldota Institute of Digestive Sciences) hospital in Mumbai... With further mentored clinical cases planned in the coming days in Delhi, Pune and Hyderabad, the expansion of Speedboat and the CROMA Advanced Energy Platform continues to gather pace. As well as India and the US, patients have now been successfully treated using the Speedboat device powered by Creo's CROMA Advanced Energy platform in the UK, South Africa and Mainland Europe. RNS: 2 December 2019 Fundraising, including Firm Placing, to raise a minimum of GBP43.0 million Launch of Accelerated Book Build and Open Offer to raise up to GBP6.6 million [issue price 180 pence] Craig Gulliford, Creo's Chief Executive Officer, commented: "The injection of additional funds ensures that we can fully capitalise on the growing opportunity that endoscopic surgery offers and will help to accelerate the commercial roll-out of our wider suite of patented electrosurgical devices powered by the CROMA Advanced Energy Platform. This also provides us with a platform to explore potential strategic acquisition opportunities in areas where we can identify adjacent technologies or infrastructure that will support our ambitious growth plans." RNS: 23 December 2019 Result of Open Offer CREO... raised total gross proceeds of GBP1.9 million via the Open Offer. Accordingly, the Company has conditionally raised total gross proceeds of GBP51.9 million via the Fundraising. RNS: 30 January 2020 Trading Update ...trading for the year ended 31 December 2019 has been in-line with expectations and the Company continues to make progress in the commercialisation of the CROMA Advanced Energy Platform ("CROMA") and a suite of patented electrosurgical devices. ...The Company expects to see significant growth during 2020 in commercial orders for its Speedboat device. It is in the final stages of agreeing a third-party manufacturing contract to facilitate larger scale production. The Company has already validated the first batches of products from the third-party manufacturer and is confident of the high quality and consistency of production. Craig Gulliford, Chief Executive Officer of Creo, commented: "Following the completion of our suite of products and the development of our distribution network over the last 12 months, the whole team is gearing up for clinical activity with multiple devices. This is based around both existing and new customers and users. The new devices include, what we believe to be, the only triple mode bipolar surgical scissors, the smallest microwave ablation device, and the only non-stick haemostasis device. "Having delivered initial revenues last year, the next few months mark a significant step up for the business. With much appreciated shareholder support, we now have a unique opportunity with game changing devices to develop the business. We are excited to be bringing these capabilities to both endoscopists and surgical users in many disciplines over the next few years. These achievements are testament to the hard work, passion and dedication of the extended Creo team." RNS: 23 March 2020 US FDA Clearance for HS1 Haemostasis Device CREO… the medical device company focused on the emerging field of surgical endoscopy, announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its HS1 Haemostasis device ('HS1'). The HS1 will be used with Creo's CROMA Advanced Energy Platform ('CROMA') and alongside the already FDA-cleared Speedboat device. This news represents a significant milestone for the Company, being the first of a number of expected regulatory clearances which will bring a suite of devices to the flexible endoscopy markets in the EU and USA... RNS: 20 May 2020 Commercialisation Agreement CREO… announces that it has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to the Company's CROMA Advanced Energy Platform ("CROMA") and associated devices for use in Gastrointestinal ("GI") therapeutic endoscopy at preferential rates for a limited period. The National Institute for Health Research ("NIHR") Invention for Innovation ("i4i") Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to GBP2 million. In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo's suite of advanced energy surgery products... RNS: 3 June 2020 Positive NHS health economics data Savings of nearly GBP5,000 per procedure using Speedboat instead of traditional surgery CREO... announces that initial data from the UK's leading user of the Company's Speedboat device demonstrates that the use of Speedboat can save NHS hospitals nearly GBP5,000 per procedure versus a traditional surgical outcome for patients. Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of GBP400,000 of NHS funding in just one hospital... ...The full data is expected to be published in October 2020 and the overall costs savings could be higher when the additional follow up costs associated with surgery is factored in. A further announcement will be made once the data is published in full. RNS: 15 June 2020 CE mark for five new devices Key commercial milestone with launch of full suite of GI products CREO… announces a key commercial milestone, with the simultaneous CE marking of five new devices which form the Creo GI (gastro-intestinal) suite of advanced energy devices across four technology platforms. The CE marking of the full range of products provides EU and UK clearance ahead of their commercial launch. Creo expects to introduce the devices into clinical practice and prepare for commercialisation in the second half of the year. The range is designed to be used with the CROMA(TM) Advanced Energy Platform (CROMA), powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures. The heavily patented devices are individually optimised to utilise Bipolar radiofrequency (RF) and High frequency microwave (MW) energy for the core tissue effects of dissection, resection, haemostasis and ablation, and form the basis of four individual device platforms... ...The newly CE marked products are: Speedboat(TM) Slim SpydrBlade(TM) Flex MicroBlate(TM) Fine MicroBlate(TM) Flex SlypSeal(TM) Flex RNS: 2 July 2020 Development loan for plasma sterilising product CREO advanced energy platform to combat COVID-19 Cardiff Capital Region City Deal funding to supports CREO Plasma Division CREO... announces that the Group has secured a GBP2m loan from the Cardiff Capital Region ("CCR") to develop Creo's Cool Plasma technology as a method to kill bacteria and viruses and for sterilisation purposes. Creo's technology has both medical and non-medical applications and initial testing has demonstrated that it can be effective for COVID-19 inactivation and decontamination. The Company believes that the technology has the potential for use in wound care, medical device sterilisation, PPE sterilisation, endoscope sterilisation to kill the bacteria associated with urinary tract infections, as well as general sterilisation and cleaning of enclosed environments within the service and transport sectors... RNS: 6 July 2020 Directorate Change, Appointment of Chief Commercial Officer to the Board & Further strengthening of Senior Management team CREO... announces the following change to the Board and strengthening of the Senior Management team. Appointment of David Woods as Executive Director (previously Non-Exec) David Woods, Non-Executive Director, has been appointed as Chief Commercial Officer ('CCO'), with effect from 1 August 2020. David has extensive experience in the med-tech sector and joins the Company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical... RNS: 24 July 2020 Acquisition of Albyn Medical S.L. Supplier of specialist healthcare products adds European commercial platform to Creo CREO... announces the acquisition of Albyn Medical S.L. ("Albyn Medical"), a European specialist in the supply and manufacture of Gastroenterology, Urology and Endoscopy products to healthcare providers, for an equity value of EUR24.8m plus up to EUR2.7m of performance related consideration payable over the next two years. Synergistic acquisition that provides immediate market access With a sales and marketing team of nearly 40 people and a direct presence in Spain, France, Germany and the UK, the acquisition of Albyn Medical fits with the strategy set out by Creo at the time of its fundraising last year and provides it with a commercial and distribution platform to accelerate the development of its business in Europe. Albyn Medical focuses on gastrointestinal ( " GI") products and the acquisition provides a direct route-to-market for Creo's full suite of CE marked GI advanced energy devices... RNS: 23 September 2020 Half-year Report Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces its unaudited results for the six-month period ended 30 June 2020, in line with management expectations... RNS: 2 November 2020 US FDA clearance for MicroBlate (TM) Fine device CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate (TM) Fine. This is the third device to gain FDA regulatory clearance within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market alongside SlypSeal(TM) Flex and Speedboat(TM) Inject. The range is designed to be used with the CROMA Advanced Energy Platform, powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures such as resection, dissection, coagulation and ablation of tissue... RNS: 3 November 2020 Acquisition of Boucart Medical SRL Belgium based supplier of GI Endoscopy products, complementing Albyn Medical's product range CREO... is pleased to announce the acquisition of Boucart Medical SRL ("Boucart Medical"), the largest independent supplier of gastrointestinal ("GI") endoscopy consumables in Belgium and Luxembourg, for an initial consideration of EUR4.5 million in cash (subject to closing adjustments for cash, debt and working capital) plus up to EUR0.5 million of performance related consideration payable in cash over the next two years... RNS: 9 December 2020 First clinical use of new Creo GI product CREO... announces the first in-man clinical use of its MicroBlate(TM) Fine device, believed to be the world's smallest fine needle microwave ablation device available for clinical practice. The device was used to successfully ablate pancreatic tumour tissue under Endoscopic Ultrasound guidance, without any procedural complications... RNS: 7 January 2021 US FDA clearance for MicroBlate (TM) Flex device CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate(TM) Flex. MicroBlate(TM) Flex is the fourth device within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market to receive FDA regulatory clearance, alongside CE marking already received across the range in 2020. The first Creo product to receive FDA clearance, Speedboat(TM) Inject, is being used by clinicians in the UK, EU, US, South Africa and APAC... RNS: 17 February 2021 Trading update Strong regulatory and commercial progress achieved despite worldwide COVID-19 restrictions CREO… announces that trading for the year ended 31 December 2020 was marginally ahead of management expectations, with revenue for the year ended 31 December 2020 increasing to over GBP9m (2019: GBP0.01m). The Company had a net cash position at 31 December 2020 in excess of GBP45m... Craig Gulliford, Chief Executive Officer of Creo, commented: "Despite COVID-19 having a short-term impact on the business, the last 12 months has been a period of transformational change for the Company. At the start of the pandemic, we asked the Creo team to focus on what they can achieve not what they can't achieve; I believe that they have done just that. "In addition to stepping up to provide our own COVID response in local communities, we have gained further CE marks and FDA regulatory approvals for our devices, organically grown talent and completed the acquisitions of Albyn Medical S.L. and Boucart Medical SRL . The regionalised nature of the Group's business hedges against pandemic related travel restrictions. With the roll out of COVID-19 vaccines underway, we look forward to realising our goals this year and beyond." RNS: 19 May 2021 Trading update Q1 trading ahead of management's expectations Increase in elective surgeries driven by need to reduce case backlogs CREO… provides an update on progress and Q1 2021 trading, which is ahead of management's expectations. As a result, the directors have upgraded guidance for year-end revenue performance by at least 10%. As previously stated, trading for the year ended 31 December 2020 was ahead of management's expectations, and the Company expects to report revenues of over GBP9m (2019: GBP0.01m) when it publishes its Audited Report and Accounts in early June... Craig Gulliford, Chief Executive Officer of Creo, commented: " The worldwide uncertainty created by COVID-19 continues; however, the team at Creo has delivered exceptional results across many fronts including, making significant clinical and technical advances, building a global commercial team, finding innovative ways to train clinicians and continuing to deliver revenue ahead of management's expectation into the new financial year. We are delighted with the progress that has been made and believe our products will have a big part to play in reducing costs associated with traditional open surgery, reducing the huge backlogs for elective surgery that have built up during the pandemic, and most importantly providing better outcomes for patients globally." RNS: 26 May 2021 Further health economics data validates technology CREO… announces that data from the paper titled: 'Cost-effectiveness analysis of Speedboat submucosal dissection in the management of large non-pedunculated colorectal polyps' demonstrates that the use of Speedboat Inject is highly likely to be a cost-effective strategy for treating both benign and malignant large non-pedunculated colorectal polyps(1) ("LNPCP") and can lead to cost savings in NHS Hospitals of over GBP10,000 per procedure versus a traditional surgical outcome for patients, a saving of approximately 50 per cent. This is double the saving of that which was first suggested and announced by Creo in June 2020... Craig Gulliford, Chief Executive Officer of Creo, commented: "We are extremely pleased to see this health economics data providing evidence that our Speedboat procedure could save the NHS over GBP10,000 per procedure. Our passion has always been to improve patient outcomes, not only through developing innovate medical devices to bring advanced energy to endoscopy, but to also offer economic benefits to healthcare providers, in turn allowing their limited resources to be applied elsewhere; this data demonstrates that. Following the commercial agreement we signed with the Department of Health and Social Care in 2020, offering health service bodies access to our devices at preferential rates, we continue our efforts to train more surgeons to use our technology, allowing the patients and NHS to benefit." RNS: 4 June 2021 Final results for the 12 months ended 31 December 2020 A Transformational Year: Significant growth and continued regulatory progress CREO… announces its audited final results for the 12 months ended 31 December 2020. The Board is pleased to be able to report that, despite the COVID-19 pandemic, the year ended 31 December 2020 was a strong period for Creo marked by significant internal development and expansion, along with the continued development of the Company's suite of devices to complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy... Financial Highlights : Total sales in the period were GBP9.4m (2019: GBP0.01m) Cash and cash equivalents of GBP45.1m at 31 December 2020 (31 December 2019: GBP81.0m) Operating loss of GBP23.5m (2019: GBP18.9m) including GBP0.7m share based payments, in line with management expectations and reflects increased R&D and commercial activities. Net cash outflow from operating activities of GBP16.3m (2019: GBP11.9m) RNS: 14 June 2021 Acquisition of freehold site for GBP4.25m Expansion of Chepstow footprint to support commercial roll-out CREO… announces that it has exchanged contracts to acquire the freehold interest in the current site of Creo House, the Company's main headquarters in Chepstow ('Unit 2'), as well as the adjacent site ('Units 6-9') for a total consideration of GBP4.25 million in cash. Creo expects to complete the acquisition in early July... Craig Gulliford, Chief Executive Officer of Creo, commented: " We are delighted to have secured the freehold of Creo House as well as the adjacent site which, subject to planning permission, will provide increased capacity to support our commercial, operational and logistic footprint across Europe; as well as providing additional manufacturing capacity for the commercial roll-out of the full suite of advanced energy devices. By acquiring these sites, we are not only showing a firm commitment to Wales, but we are also giving our workforce even greater stability. The expansion is reflective of the rapid growth within Creo." RNS: 16 June 2021 MicroBlate Fine's first in-human use update Life-changing FDA cleared Creo device successful in adding months to patient's life expectancy and well-being CREO… provides an update on its 510(k) US Food & Drug Administration ('FDA') cleared tissue ablation device MicroBlate(TM) Fine... Craig Gulliford, Chief Executive Officer of Creo, commented: "We are delighted to report such a positive update on our 510(k) US Food & Drug Administration cleared tissue ablation device MicroBlate(TM) Fine. The device was successfully used for the first in-human minimally invasive EUS guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour in December 2020. The outcome of the procedure was a success, with subsequent follow up scans not only showing no return of the tumour, but also an absence of any obvious scar tissue."
Creo Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CREO
Creo Medic..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210624 06:22:04